IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

JESSICA DINICOLA,

Plaintiff,

vs.

COMPLAINT AND DEMAND FOR JURY TRIAL

BAYER HEALTHCARE PHARMACEUTICALS, INC.,

Civil Case No.:

Defendant.

Plaintiff by and through the undersigned counsel, hereby alleges against Bayer Healthcare Pharmaceuticals, Inc., the following:

INTRODUCTION

1. Plaintiff brings this case against Defendant for injuries caused by the Mirena intrauterine device ("IUD") because it caused physical injury after it was properly inserted by a healthcare provider who followed Defendant's instructions and/or training.

THE PARTIES

- 2. At all relevant times, Plaintiff was a citizen and resident of Connecticut, residing in Waterbury, Connecticut.
- 3. Defendant Bayer Healthcare Pharmaceuticals, Inc. is a corporation organized and existing under the laws of the state of Delaware with its primary place of business in Wayne, New Jersey.

- 4. Defendant is in the business of designing, manufacturing, marketing, formulating, testing, packaging, labeling, producing, creating, making, constructing, assembling, advertising, and distributing prescription drugs and women's healthcare products, including the Mirena IUD.
- 5. Defendant conducts business in Connecticut and this district, including selling its Mirena IUD.
- 6. Defendant was formerly known as Berlex, Inc., which was formerly known as Berlex Laboratories, Inc. and is the same corporate entity as Berlex, Inc. and Berlex Laboratories, Inc.
- 7. Defendant is the holder of the approved New Drug Application ("NDA") for the Mirena IUD.
- 8. Defendant regularly and routinely conducts business in Connecticut and this jurisdiction through the sale of Mirena and other products.
- 9. At all times alleged herein, Defendant includes and included any and all parents, subsidiaries, affiliates, divisions, franchises, partners, joint venturers, and organizational units of any kind, their predecessors, successors and assigns and their officers, directors, employees, agents, representatives and any and all other persons acting on its behalf.
- 10. At all times relevant, Defendant was engaged in the business of developing, designing, licensing, manufacturing, distributing, selling, marketing, and/or introducing into interstate commerce throughout the United States, either

directly or indirectly through third parties, subsidiaries or related entities, the Mirena IUD.

JURISDICTION AND VENUE

- 11. This Court has jurisdiction over this action pursuant to 28 U.S.C. § 1332, because the amount in controversy as to the Plaintiff exceeds \$150,000.00, exclusive of interest and costs, and because complete diversity exists between the parties, as Plaintiff is a citizen of Connecticut, which is different from the states where Defendant is incorporated and has its principal places of business.
- 12. This Court has supplemental jurisdiction over the remaining common law and state claims pursuant to 28 U.S.C. § 1367.
- 13. Venue is proper in this Court pursuant to 28 U.S.C. § 1391 because Defendant is subject to personal jurisdiction in accordance with 28 U.S.C. § 1391(c) and because a substantial part of the events giving rise to Plaintiff's claims occurred in this jurisdiction.
- 14. This action includes claims for injuries to Plaintiff caused by the insertion of a Mirena IUD and therefore should be transferred to Multidistrict Litigation No. 2434 · In Re: Mirena IUD Products Liability Litigation, United States District Court for the Southern District of New York, the Honorable Cathy Seibel.

FACTUAL BACKGROUND

15. Mirena is an intrauterine contraceptive system that is designed to be inserted into the uterus by a healthcare provider during an office visit.

- 16. The Food and Drug Administration ("FDA") approved Defendant's NDA for Mirena in December 2000.
- 17. The Mirena IUD is approved to remain in the uterus for up to five years.
- 18. Mirena has a T-shaped polyethylene frame with a steroid reservoir that contains 52 mg of levonorgestrel.
 - 19. Levonorgestrel is a prescription medication used as a contraceptive.
 - 20. Mirena is intended to release 20 mcg of levonorgestrel each day.
- 21. Mirena does not necessarily release the intended amount. Rather, it releases approximately 20 mcg of levonorgestrel each day, and the daily amount decreases progressively over time.
- 22. The total serum concentration of levonorgestrel in women using Mirena has been measured as high as 332 mcg and as low as 52 mcg between one and two years after insertion.
- 23. The Defendant does not know why the serum concentration of levonorgestrel varies so widely in different users of Mirena.
- 24. It is generally known that long-term use of progestins, including levonorgestrel, results in a thinner uterine wall.
- 25. The Defendant does not know exactly how Mirena works, but it may thicken cervical mucus, thin the uterine lining, or inhibit sperm movement and reduce sperm survival, to prevent pregnancy.

- 26. The Mirena label warns that the device may perforate the uterus during insertion, but does not warn about rates of embedment or spontaneous perforation, migration, organ damage, infertility, or the risk of the need for surgical intervention, including after successful insertion.
 - 27. The Mirena label describes perforation as an "uncommon" event.
- 28. Defendant knew or should have known that the risk of uterine embedment and perforation is increased until as long as six months post-partum, but failed to warn of this risk.
- 29. Defendant knew or should have known the magnitude of increased risk of embedment and perforation among lactating women, but failed to disclose this information.
- 30. Defendant has a history of overstating the efficacy of Mirena while understating its risks and safety concerns.
- 31. In or around December 2009, Defendant was contacted by the Department of Health and Human Services' Division of Drug Marketing, Advertising, and Communications ("DDMAC") regarding a consumer-directed program entitled "Mirena Simple Style Statements Program," a live presentation designed for "busy moms." The Simple Style program was presented in a consumer's home or other private setting by a representative from "Mom Central", a social networking internet site, and Ms. Barb Dehn, a nurse practitioner, in partnership with Defendant.

- 32. This Simple Style program represented that Mirena use would increase the level of intimacy, romance and emotional satisfaction between sexual partners. DDMAC determined that these claims were unsubstantiated and, in fact, pointed out that Mirena's package insert states that at least 5% of clinical trial patients reported a decreased libido after use.
- 33. The Simple Style program script also intimated that Mirena use can help patients "look and feel great." Again, DDMAC noted these claims were unsubstantiated and that Mirena can cause a number of side effects, including weight gain, acne, and breast pain or tenderness.
- 34. The portion of the Simple Style script regarding risks omitted information about serious conditions, including susceptibility to infections and the possibility of miscarriage if a woman becomes pregnant while using Mirena.
- 35. Finally, Defendant falsely claimed in this advertisement that Mirena required no compliance with a monthly routine.
- 36. Soon after the first sales of Mirena, and with increasing incidence up until the present, Defendant has received notice of complications with the use of the IUD including embedment in the wall of the uterus, perforation of the uterus, and the need for surgical intervention after successful insertion.
- 37. The embedment, perforations, and the need for surgical removal, including after successful insertion, are caused by the defective design of Defendant's Mirena IUD.

- 38. Although Defendant received reports of embedment, perforation, organ damage, infertility, and the need for surgical removal, including after successful insertion, it failed to study the rate at which these injuries were occurring, and failed to disclose these risks and rates.
- 39. Defendant failed to issue warnings of the risks associated with the Mirena IUD that were commensurate with the risks of which they were aware, and Defendant concealed the knowledge it had of the risks from Plaintiff, her prescriber, the medical profession generally and from governmental regulatory bodies including the FDA.
- 40. Upon information and belief, in approximately April, 2009, Dr. Logiudice at Specialists in Women's Healthcare discussed placing a Mirena IUD in Plaintiff Jessica Dinicola. Dr. Logiudice discussed the risks and benefits of the Mirena IUD. Because Defendant did not disclose the true risks of perforation, migration and embedment of the Mirena device to Dr. Logiudice, nor did Defendant disclose the true risks of perforation, migration and embedment in the information given to Plaintiff, it was impossible for Dr. Logiudice to adequately discuss the true risks and benefits of the Mirena IUD with Plaintiff. Consequently, it was impossible for Plaintiff to learn of the true risks of the Mirena IUD.
- 41. Plaintiff, after a consultation with Dr. Logiudice, had the Mirena device implanted by Dr. Logiudice on or about April 15, 2009. The Mirena IUD implanted in Plaintiff remained in substantially the same condition between when it left Defendant's control and when it was implanted in Plaintiff. Dr. Logiudice

would not have implanted the Mirena in Plaintiff if Dr. Logiudice knew of the true risks of the Mirena IUD. In other words, Dr. Logiudice would not have implanted the Mirena device in Plaintiff if Dr. Logiudice knew the true rate of migration, embedment and perforation of the Mirena.

- 42. Plaintiff would not have elected to have the Mirena IUD implanted in her if she knew of the true risks associated with the use of Mirena. In other words, Ms. Dinicola would not have elected to have the Mirena device implanted in her if she knew the true rate of migration, embedment and perforation of the Mirena IUD.
- 43. By 2011, the Mirena IUD migrated. Upon information and belief, testing showed that the Mirena IUD had migrated and was not located in the proper position. The Mirena IUD migrated because it was negligently and defectively designed. Defendant knew that the Mirena IUD was negligently and defectively designed when it left Defendant's control, and Defendant knew that it migrated at a higher rate than other IUDs on the market. Defendant did not disclose these facts to Dr. Logiudice or Ms. Dinicola.
- 44. Through no fault of her own, and no fault of her physician, on August 25, 2011, Plaintiff had the Mirena IUD surgically removed because it had migrated and was no longer located in the proper position. The surgery caused pain and suffering, financial loss and caused permanent injury to Plaintiff, including a scar and permanent risk of placenta accreta.

CAUSES OF ACTION

COUNT I STRICT PRODUCTS LIABILITY - MANUFACTURING DEFECT

- 45. Plaintiff incorporates each paragraph of this Complaint as if set forth fully here, and further alleges as follows.
- 46. Mirena was designed, manufactured, marketed, promoted, sold, and introduced into the stream of commerce by Defendant.
- 47. When it left the control of Defendant, the IUD was expected to, and did reach Plaintiff without substantial change from the condition in which it left Defendant's control.
- 48. The IUD was defective when it left Defendant's control and was placed in the stream of commerce, in that there were foreseeable risks that exceeded the benefits of the product and/or that it deviated from product specifications and/or applicable federal requirements, and posed a risk of serious injury and death.
- 49. Specifically, the device was more likely than other similar devices to embed, migrate, cause perforation, organ damage, or infertility, and require surgical removal, including after successful insertion.
- 50. The IUD was inserted into Plaintiff in substantially the same condition it was in when it left control of Defendant and any changes or modifications were foreseeable by Defendant.
- 51. Plaintiff and her healthcare providers did not misuse or materially alter the Mirena device.

- 52. As a direct and proximate result of the Plaintiff's use of the IUD, she suffered serious physical injury, harm, damages and economic loss, and will continue to suffer such harm, damages and economic loss in the future.
- 53. Defendant is strictly liable to Plaintiff for designing, creating, manufacturing, distributing, selling, and placing Mirena into the stream of commerce, and for all damages caused to Plaintiff by her use of Mirena because the product was defective.
- 54. Defendant's actions and omissions as alleged in this Complaint constitute a flagrant disregard for human life, so as to warrant the imposition of punitive damages.

COUNT II STRICT PRODUCTS LIABILITY – DESIGN DEFECT

- 55. Plaintiff incorporates each paragraph of this Complaint as if set forth fully here, and further alleges as follows.
- 56. The IUD was not merchantable and/or reasonably suited to the use intended, and its condition when sold was the proximate cause of the injuries sustained by Plaintiff.
- 57. Defendant placed Mirena into the stream of commerce with wanton and reckless disregard for the public safety.

- 58. Mirena was defective in design in that, when it left Defendant's control, the foreseeable risks of the product exceeded the benefits associated with its design, and it was more dangerous than an ordinary consumer or ordinary healthcare provider would expect.
- 59. The foreseeable risks associated with Mirena's design include the fact that its design is more dangerous than a reasonably prudent consumer or healthcare provider would expect when used in an intended or reasonably foreseeable manner.
- 60. Mirena was in an unsafe, defective, and inherently dangerous condition, which was unreasonably dangerous to its users and in particular, Plaintiff.
- 61. Mirena was in a defective condition and unsafe, and Defendant knew, had reason to know, or should have known that Mirena was defective and unsafe, even when used as instructed.
- 62. The nature and magnitude of the risk of harm associated with the design of Mirena, including embedment, migration, perforation, organ damage, infertility, and the need for surgical removal, including after successful insertion, is high in light of the intended and reasonably foreseeable use of Mirena.
- 63. The risks of harm associated with the design of Mirena are higher than necessary and higher than with other forms of reversible contraception and other IUDs.

- 64. It is highly unlikely that Mirena users would be aware of the risks associated with Mirena through either warnings, general knowledge or otherwise, and Plaintiff specifically was not aware of these risks.
- 65. The design did not conform to any applicable public or private product standard that was in effect when Mirena left the Defendant's control.
- 66. Mirena's design is more dangerous than a reasonably prudent consumer would expect when used in its intended or reasonably foreseeable manner as a reversible form of contraceptive. It was more dangerous than Plaintiff expected.
- 67. The intended or actual utility of Mirena is not of such benefit or to justify the risk of embedment, migration, perforation, organ damage, infertility, the need for surgical removal, including after successful intervention.
- 68. At the time the Mirena IUD left Defendant's control, it was both technically and economically feasible to have an alternative design that would not cause embedment, migration, perforation, organ damage, infertility, the need for surgical removal, including after successful insertion, or an alternative design that would have substantially reduced the risk of these injuries.
- 69. It was both technically and economically feasible to provide a safer alternative design that would have prevented the harm suffered by Plaintiff.
- 70. The unreasonably dangerous nature of Mirena caused serious harm to Plaintiff.

71. As a direct and proximate result of the Plaintiff's use of the Mirena IUD, which was designed, manufactured, marketed, promoted, sold, and introduced into the stream of commerce by Defendant, Plaintiff suffered serious physical injury, harm, damages and economic loss and will continue to suffer such harm, damages and economic loss in the future.

WHEREFORE, Plaintiff respectfully requests an award of compensatory and punitive damages, in addition to all costs, interest and fees, including attorneys' fees, to which she is entitled under law and such other relief as this Honorable Court deems appropriate.

COUNT III STRICT PRODUCTS LIABILITY – FAILURE TO WARN

- 72. Plaintiff incorporates each paragraph of this Complaint as if set forth fully here, and further alleges as follows.
- 73. Defendant had a duty to warn Plaintiff and her healthcare providers of the risk of embedment, migration, perforation, organ damage, infertility and surgical removal of Mirena, including such risks after successful insertion.
- 74. Defendant knew, or in the exercise or reasonable care should have known, about the risk of embedment, migration, perforation, organ damage, infertility, and the need for surgical intervention, including after successful insertion.
- 75. Defendant failed to provide warnings or instructions that a manufacturer exercising reasonable care would have provided concerning the risk of embedment, migration, perforation, organ damage, infertility, and the need for

surgical removal, including after successful insertion, in light of the likelihood that its product would cause these injuries.

- 76. Defendant failed to update warnings based on information received from product surveillance after Mirena was first approved by the FDA and marketed, sold, and used in the United States and throughout the world.
- 77. A manufacturer exercising reasonable care would have updated its warnings on the basis of reports of injuries to women using Mirena after FDA approval.
- 78. When it left Defendant's control, the Mirena IUD was defective and unreasonably dangerous for failing to warn of the risk of embedment, migration, perforation, organ damage, infertility and the need for surgical removal, including after successful insertion.
- 79. Plaintiff used the IUD for its approved purpose and in a manner normally intended and reasonably foreseeable by the Defendant.
- 80. Plaintiff and Plaintiff's healthcare providers could not, by the exercise of reasonable care, have discovered the defects or perceived their danger because the risks were not open or obvious.
- 81. Defendant, as the manufacturer and distributor of the device, is held to the level of knowledge of an expert in the field.
- 82. The warnings that were given by Defendant were not accurate or clear, and were false and ambiguous.

- 83. The warnings that were given by the Defendant failed to properly warn physicians of the risks associated with its device, subjecting Plaintiff to risks that exceeded the benefits to the Plaintiff. Plaintiff, individually and through her physician, reasonably relied upon the skill, superior knowledge and judgment of the Defendant.
- 84. Defendant had a continuing duty to warn Plaintiff and her prescriber of the dangers associated with its product.
- 85. Had Plaintiff or her healthcare providers received adequate warnings regarding the risks associated with the use of the Mirena IUD, she would not have used it, but would instead have used other means for contraception.
- 86. As a direct and proximate result of the Plaintiff's use of the IUD and Plaintiff's reliance on Defendant's representations regarding the character and quality of the product and Defendant's failure to comply with federal requirements, Plaintiff suffered serious physical injury, harm, damages and economic loss and will continue to suffer such harm, damages and economic loss in the future.

COUNT IV NEGLIGENCE

87. Plaintiff incorporates each paragraph of this Complaint as if set forth fully here, and further alleges as follows.

- 88. Defendant had a duty to exercise reasonable and ordinary care in the design, manufacture, sale, testing, quality assurance, quality control, labeling, marketing, promotions, and distribution of Mirena into the stream of commerce, including a duty to assure that its product did not pose an undue risk of bodily harm and adverse events, and to properly warn of all risks, and comply with federal requirements.
- 89. Defendant failed to exercise reasonable and ordinary care in the design, manufacture, sale, testing, quality assurance, quality control, labeling, marketing, promotions and distribution of Mirena into the stream of commerce in that Defendant knew or should have known that the product caused significant bodily harm and was not safe for use by consumers. Specifically, Defendant failed to properly and thoroughly:
 - a. Test Mirena before releasing it into the market;
 - b. Analyze the data resulting from the pre-marketing tests of Mirena;
 - c. Conduct sufficient post-market testing and surveillance of Mirena; and
 - d. Provide appropriate warnings for consumers and healthcare providers including disclosure of the known or potential risks or true or suspected rates of embedment, migration, perforation, organ damage, infertility, surgical intervention, including after successful insertion, spontaneous migration, spontaneous perforation, spontaneous organ damage, or infertility.

- 90. Despite the fact that Defendant knew or should have known that its product posed a serious risk of bodily harm to consumers, Defendant continued to manufacture and market Mirena for use by consumers and continued to fail to comply with federal requirements.
- 91. Defendant knew or should have known that consumers such as Plaintiff would foreseeably suffer injury as a result of Defendant's failure to exercise ordinary care as described above, including the failure to comply with federal requirements.
- 92. It was foreseeable that Defendant's product, as designed, would cause serious injury to consumers, including Plaintiff.
- 93. As a direct and proximate result of Defendant's negligence, Plaintiff suffered serious physical injury, harm, damages and economic loss and will continue to suffer such harm, damages and economic loss in the future.
- 94. Defendant's conduct as described above, including but not limited to its failure to adequately design, test, and manufacture, as well as its continued marketing and distribution of the Mirena IUD when it knew or should have known of the serious health risks it created and the failure to comply with federal requirements, evidences a flagrant disregard of human life so as to warrant the imposition of punitive damages.
- 95. Defendant's actions and omissions as alleged in this Complaint demonstrate a flagrant disregard for human life, and willful and wonton conduct, which warrants the imposition of punitive damages.

COUNT V BREACH OF EXPRESS WARRANTY

- 96. Plaintiff incorporates each paragraph of this Complaint as if set forth fully here, and further alleges as follows.
- 97. Defendant expressly warranted that its Mirena IUD was a safe and effective device for women seeking contraception, and did not disclose the material risks that Mirena could embed, migrate, cause perforation, organ damage, infertility, or require surgical intervention, including after successful insertion.
 - 98. The representations were not justified by the performance of Mirena.
- 99. Members of the consuming public, including consumers such as Plaintiff, and her healthcare providers, were intended third party beneficiaries of the warranty.
- 100. Plaintiff and her healthcare providers reasonably relied on these express representations.
- 101. The IUD manufactured and sold by Defendant did not conform to these express representations because it caused serious injury to the Plaintiff when used as recommended and directed, and these risks were not disclosed to Plaintiff or her healthcare providers.

102. As a direct and proximate result of Defendant's breach of warranty, Plaintiff suffered serious physical injury, harm, damages and economic loss and will continue to suffer such harm, damages and economic loss in the future.

WHEREFORE, Plaintiff respectfully requests an award of compensatory and punitive damages, in addition to all costs, interest and fees, including attorneys' fees, to which she is entitled under law and such other relief as this Honorable Court deems appropriate.

COUNT VI BREACH OF IMPLIED WARRANTY

- 103. Plaintiff incorporates each paragraph of this Complaint as if set forth fully here, and further alleges as follows.
- 104. When Defendant designed, manufactured, marketed, sold, and distributed its Mirena IUD for use by the Plaintiff, Defendant knew of the use for which it was intended and impliedly warranted the product to be of merchantable quality and safe for such use and that its design, manufacture, labeling, and marketing complied with all applicable federal requirements.
- 105. Plaintiff and her physicians reasonably relied upon the Defendant's representations of the product's merchantable quality and that it was safe for its intended use, and upon Defendant's implied warranty, including that it was in compliance with all federal requirements.
- 106. Contrary to such implied warranty, the Mirena IUD was not of merchantable quality or safe for its intended use, because the product was defective, as described herein, and it failed to comply with federal requirements.

107. As a direct and proximate result of Defendant's breach of warranty, the Plaintiff suffered serious physical injury, harm, damages and economic loss and will continue to suffer such harm, damages and economic loss in the future.

WHEREFORE, Plaintiff respectfully requests an award of compensatory and punitive damages, in addition to all costs, interest and fees, including attorneys' fees, to which she is entitled under law and such other relief as this Honorable Court deems appropriate.

COUNT VII FRAUD AND MISREPRESENTATION

- 108. Plaintiff incorporates each paragraph of this Complaint as if set forth fully here, and further alleges as follows.
- 109. Defendant falsely and fraudulently represented to the medical and healthcare community and to the Plaintiff, as well as to the FDA, and the public in general, that the product had been tested and was found to be safe for use.
 - 110. The representations made by the Defendant were, in fact, false.
- 111. When these representations were made by the Defendant, it knew those representations to be false and/or willfully, wantonly, and recklessly disregarded whether the representations were false.
- 112. Defendant knowingly and intentionally made false representations of material fact to Plaintiff, including but not limited to claims that its IUD product was safe and/or that it had adequately disclosed all risks of use.
- 113. These representations were made by the Defendant with the intent of defrauding and deceiving the Plaintiff, the public in general, and the medical and

healthcare community in particular, and were made with the intent of inducing Plaintiff, the public in general, and the medical and healthcare community in particular, to recommend, prescribe, dispense and purchase the product, all of which evinced a callous, reckless, willful, depraved indifference to the health, safety and welfare of the Plaintiff and the public in general.

- 114. When these representations were made by Defendant and when Plaintiff utilized the Mirena device, she and her physician reasonably believed them to be true and were unaware that they were false.
- 115. In reliance on these representations, Plaintiff was induced to, and did use the product, and her healthcare providers were induced to, and did prescribe and insert the product. As a result, Plaintiff sustained severe and permanent personal injuries including but not limited to significant pain, irritation and discomfort, economic damage, and other severe and permanent health consequences, notwithstanding the Defendant's knowledge of the risk of these injuries and side effects.
- 116. Defendant knew and was aware, or should have been aware that Mirena had not been sufficiently tested, was defective in nature, and/or that it lacked adequate and/or sufficient warnings.
- 117. Defendant knew or should have known that its product had a potential to, and would cause severe and grievous injury to the users of product, and that it was inherently dangerous in a manner that exceeded its inaccurate, and downplayed warnings.

- 118. Defendant brought the Mirena IUD to the market and acted fraudulently, wantonly, and maliciously, to the detriment of the Plaintiff.
- 119. As a direct and proximate result of Defendant's fraudulent misrepresentations and omissions and/or their failure to disclose their violations of federal requirements applicable to their product, Plaintiff used Mirena and suffered serious physical injury, harm, damages and economic loss and will continue to suffer such harm, damages.

COUNT VIII CONSUMER FRAUD - VIOLATION OF CONSUMER PROTECTION STATUTES

- 120. Plaintiff incorporates each paragraph of this Complaint as if set forth fully here, and further alleges as follows.
- 121. The Defendant used and employed unconscionable commercial practices, deception, fraud, false pretenses, false promises and misrepresentations, and knowingly concealed, suppressed and omitted material facts in connection with the sale, advertisement and promotion of its Mirena IUD, in violation of all applicable state consumer fraud statutes, with the intent that consumers, including Plaintiff and her physician, rely upon such concealment, suppression and omission, and for the purpose of influencing and inducing physicians and medical providers to prescribe it for patients/consumers such as the Plaintiff. By reason of

the Defendant's unconscionable, deceptive and fraudulent acts and practices, and false pretenses, false promises and misrepresentations, reasonable patients/consumers acting reasonably, such as the Plaintiff, were caused to suffer ascertainable loss of money and property and actual damages.

- 122. Defendant engaged in consumer-oriented, commercial conduct by selling and advertising the Mirena IUD.
- 123. Defendant misrepresented and omitted material information regarding the Mirena IUD by failing to disclose known risks.
- 124. The Defendant's misrepresentations and concealment of material facts constitute unconscionable commercial practices, deception, fraud, false pretenses, misrepresentation, and/or the knowing concealment, suppression, or omission of materials facts with the intent that others rely on such concealment, suppression, or omission in connection with the sale and advertisement of the Mirena IUD.
- 125. Defendant's actions violated Conn. Gen. Stat. §§ 42-110a, et seq. and 21a-216, et seq., and other applicable state consumer protection statutes.
- 126. Mirena is a "Product" within the meaning of these statutes, and at all times relevant to this action, Defendant conducted trade and commerce within the meaning of these statutes, and Plaintiff and Defendant are "persons" within the meaning of these statutes.
- 127. Defendant's statements and omissions were undertaken with the intent that the FDA, physicians, healthcare providers, and consumers, including

Plaintiff, would rely on the Defendant's false and deceptive statements and omissions.

- 128. Plaintiff's physicians and healthcare providers prescribed Mirena to Plaintiff, who suffered ascertainable losses of money and property as a result of Defendant's fraudulent methods, acts, practices, and sale of Mirena.
- 129. Defendant, through its officers, directors, agents, representatives, managers, and employees, are the researchers, developers, designers, testers, manufacturers, inspectors, labelers, distributors, marketers, promoters, releasers, and sellers of Mirena into the stream of commerce.
- 130. This jurisdiction and Connecticut have enacted statutes to protect consumers from deceptive, fraudulent, and unconscionable trade and business practices. Defendant violated these statutes by knowingly and falsely representing that the Mirena IUD was fit to be used for the purpose for which it was intended, when the Defendant knew it was defective and dangerous, failed to properly warn of material risks associated with its use, and by other acts alleged herein.
- 131. Defendant engaged in the deceptive acts and practices to sell the Mirena IUD to the public, including Plaintiff.
- 132. As a direct and proximate result of the Defendant's violations of various consumer protection statutes, Plaintiff has suffered damages, for which she is entitled to compensatory damages, equitable and declaratory relief, punitive damages, costs and reasonable attorneys' fees.

133. As a direct and proximate result of Defendant's conduct, Plaintiff used the Mirena IUD and suffered serious physical injury, harm, damages and economic loss and will continue to suffer such harm, damages and economic loss in the future.

WHEREFORE, Plaintiff respectfully requests an award of compensatory and punitive damages, in addition to all costs, interest and fees, including attorneys' fees, to which she is entitled under law and such other relief as this Honorable Court deems appropriate.

COUNT IX NEGLIGENT MISREPRESENTATION

- 134. Plaintiff incorporates each paragraph of this Complaint as if set forth fully here, and further alleges as follows.
- 135. Defendant, through its marketing and other actions, misrepresented that Mirena was safe and did not pose a risk of embedment, migration, perforation, organ damage, infertility, or surgical intervention, including after successful insertion.
- 136. Defendant made these misrepresentations to induce Plaintiff and others to use Mirena and Plaintiff's and other's healthcare providers to prescribe Mirena, to gain profit.
- 137. Given the information available to the Defendant, it was not reasonable for the Defendant to believe that its misrepresentations were true.

 Instead, Defendants knew or should have known its representations were false and that it should have conducted further tests and studies to measure the likelihood of

embedment, migration, perforation, organ damage, infertility, and surgical intervention, including after successful insertion, and should have disclosed those risks to patients and healthcare providers, including Plaintiff and Plaintiff's healthcare providers.

- 138. Plaintiff and Plaintiff's healthcare providers reasonably relied on Defendant's misrepresentations.
- 139. In the absence of these misrepresentations, Plaintiff would not have used Mirena.
- 140. As a direct and proximate result of Defendant's conduct, Plaintiff used the Mirena IUD and suffered serious physical injury, harm, damages and economic loss and will continue to suffer such harm, damages and economic loss in the future.

WHEREFORE, Plaintiff respectfully requests an award of compensatory and punitive damages, in addition to all costs, interest and fees, including attorneys' fees, to which she is entitled under law and such other relief as this Honorable Court deems appropriate.

COUNT X FRAUDULENT MISREPRESENTATION

- 141. Plaintiff incorporates each paragraph of this Complaint as if set forth fully here, and further alleges as follows.
- 142. Defendant's misrepresentations were made of a presently existing fact with knowledge that the representations were untrue.

- 143. Defendant intended for Plaintiff and her healthcare providers to rely on their misrepresentations.
- 144. Plaintiff and her healthcare providers reasonably relied on Defendant's misrepresentations and suffered an injury as a result.

COUNT XI NEGLIGENT INFLICTION OF EMOTIONAL DISTRESS

- 145. Plaintiff incorporates each paragraph of this Complaint as if set forth fully here, and further alleges as follows.
 - 146. The Defendant was negligent, as alleged herein.
- 147. As a result of Defendant's negligence, Plaintiff suffered serious emotional distress.
- 148. Defendant's negligence was the proximate cause and a substantial factor in causing Plaintiff's serious emotional distress in that she would not have suffered this distress absent injury caused by Defendant.
 - 149. It was not reasonable to expect Plaintiff to suffer this distress.

WHEREFORE, Plaintiff respectfully requests an award of compensatory and punitive damages, in addition to all costs, interest and fees, including attorneys' fees, to which she is entitled under law and such other relief as this Honorable Court deems appropriate.

COUNT XII UNJUST ENRICHMENT

- 150. Plaintiff incorporates each paragraph of this Complaint as if set forth fully here, and further alleges as follows.
- 151. Defendant is, and at all times relevant to this action was, the manufacturer, seller, and supplier of Mirena.
- 152. Plaintiff was prescribed and billed for Mirena for the purpose for which it was intended, and in reliance upon Defendant's representations of the safety and efficacy of the product.
- 153. Defendant has accepted payments from Plaintiff, other consumers, and third party payors for the purchase of Mirena, totaling hundreds of millions of dollars in revenue and financial gain from the sale of the unsafe product.
- 154. Plaintiff did not receive the safe and effective product for which she was billed, and equity therefore demands that Defendant be disgorged of its profits received from sales of the defective products and its own deception regarding the safety and efficacy of the drug.

WHEREFORE, Plaintiff respectfully requests an award of compensatory and punitive damages, in addition to all costs, interest and fees, including attorneys' fees, to which she is entitled under law and such other relief as this Honorable Court deems appropriate.

PRAYER FOR RELIEF

Plaintiff respectfully requests judgment against Defendant on each of the above counts as follows:

- a. Compensatory damages to Plaintiff for past and future damages, including but not limited to pain and suffering for severe and permanent personal injuries, healthcare costs, medical monitoring, together with all interest and costs as provided by the law;
- b. Punitive and exemplary damages for the wanton, willful, fraudulent, and reckless acts of Defendant who demonstrated a complete disregard and reckless indifference for the safety and welfare of the general public and Plaintiff, in an amount sufficient to punish Defendant and deter future similar conduct;
- c. Treble damages for violation of consumer protection statutes;
- d. Plaintiff's attorney fees;
- e. Plaintiff's costs of the proceedings; and
- f. Such other and further relief as this Court deems just and proper.

DEMAND FOR JURY TRIAL

The Plaintiff hereby demands a trial by jury on all counts and as to all issues.

Dated: <u>July 31, 2013</u> Respectfully Submitted,

Dianne M. Nast (PA Atty. ID No. 24424)

Daniel N. Gallucci (PA Atty. ID No. 81995)

Joanne E. Matusko (PA Atty. ID No. 91059)

NASTLAW, LLC

1101 Market Street, Suite 2801

Philadelphia, Pennsylvania 19107

Telephone: (215) 923-9300

Facsimile: (215) 923-9302

Email: dnast@nastlaw.com dgallucci@nastlaw.com jmatusko@nastlaw.com

James J. McHugh, Jr. Joshua M. Mankoff LOPEZ MCHUGH, LLP 1123 Admiral Peary Way Quarters K Philadelphia, PA 19112 Telephone: 215-952-9610

Facsimile: 215-952-6914

Email: jmankoff@lopezmchugh.com

Attorneys for Plaintiff